EMD Millipore to Acquire Exclusive Rights to Singulex’s Technology


EMD Millipore and Singulex recently announced they have entered into a definitive agreement under which EMD Millipore will control and manage the Singulex Life Science Research business. Under the terms of the agreement, EMD Millipore will pay Singulex an upfront payment, royalties, and additional payments based upon achievement of certain commercial milestones. EMD Millipore will have exclusive rights to further develop and commercialize the SMC technology for research applications worldwide.

Reliable, ultra-sensitive protein detection is a critical unmet need in life science research. Current technologies allow detection of only approximately 5% of proteins in the entire proteome due to the very low abundance of many biomarkers, leaving the vast majority of proteins virtually undetectable. The SMC technology is a novel, patented technology combining signal enhancement and background reduction coupled with low volume sampling to achieve ultra-high sensitivity protein detection. The clinical benefits of this technology have been well-established, and Singulex will continue to operate a large and successful clinical service business based on novel, enabling SMC assays. Financial and other terms of the deal were not disclosed.

“This agreement is further evidence of EMD Millipore’s commitment to bringing innovative technologies to our global life science customers,” said Udit Batra, President and CEO of EMD Millipore. “The Erenna platform offers the unique advantage of unrivaled sensitivity and precision and will be a strong addition to our Protein Detection franchise.”

“We are very pleased with this strategic agreement with EMD Millipore, a world leader in life science, since it puts our unique technology into the best possible hands to optimize its commercial scale-up and market potential,” added Guido Baechler, President and CEO of Singulex. “We have established our position as a leader in high-sensitive immunoassays, and this deal enables us to leverage our superior immunoassay technology to create additional opportunities in our other diagnostic businesses, especially within the area of companion diagnostics.

EMD Millipore is the US Life Science subsidiary of Merck KGaA, Darmstadt, Germany. As part of the global Life Science business of Merck KGaA, Darmstadt, Germany, EMD Millipore offers a broad range of innovative, performance products, services, and business relationships that enable its customers’ success in research, development, and production of biotech and pharmaceutical drug therapies. For more information, visit www.emdmillipore.com

Singulex is the developer and leading provider of Single Molecule Counting technology for clinical diagnostics and scientific discovery. Singulex’s proprietary SMC technology enables physicians and scientists to detect biomarkers of disease that were previously undetectable. Powered by SMC technology, Singulex’s ultrasensitive immunoassay solutions and lab testing services are transforming patient care from reactive disease treatment to proactive health management and fueling the discovery and development of new therapeutics. For more information, visit www.singulex.com.

Share This